Researchers say Tamiflu a waste of money

Share this article:

One hundred and seventy thousand pages of data have led researchers to one conclusion: Roche's Tamiflu and GlaxoSmithKline's Relenza were a waste of money.

Published in BMJ, the researchers said that while the drugs could have an impact on flu symptoms, they were worthless in terms of containing a flu pandemic, which was the key reason governments spent billions stockpiling the medications.

Bloomberg reports the US has paid $1.3 billion and the UK $710 million on medications researchers said reduced patient misery by 17 hours but “without curbing the number of hospitalizations.”

BMJ's editor-in-chief said at a briefing that this is coming out because researchers now have access to clinical trial data they had been seeking since 2009, when the H1N1 swine flu broke and governments started ramping up their stores.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies